Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Cabozantinib vs Cabozantinib in Advanced RCC Post-ICI
NCT04338269Phase 3Terminated
- Sponsor
- Roche
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of atezolizumab in renal cell carcinoma (RCC), sponsored by Roche. Started Jul 2020; status: terminated.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04338269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338269.